重复立体定向放射外科治疗库欣病:一项国际多中心研究的结果
该国际多中心研究汇总5家机构20例初次立体定向放射外科(SRS)后≥12个月复发或持续库欣病患者,重复单次SRS后中位内分泌随访6.6年,12例(60%)获内分泌缓解,5年和10年持久缓解率分别为47%和53%,2例(10%)出现放射不良反应。
要点
- 重复SRS后60%(12/20)患者获内分泌缓解,中位缓解时间6个月。
- 5年和10年持久内分泌缓解率分别为47%和53%。
- 2例(10%)出现放射不良反应,包括短暂视力丧失和永久性复视。
核心结论
- 重复SRS可使约半数经先前显微手术和SRS均难治的库欣病患者获得持久生化缓解。
- 鉴于难治性或复发性库欣病的致残风险,对初次SRS后≥1年确认高皮质醇血症的经仔细选择的患者应考虑重复SRS。
研究设计与样本
- 研究汇总国际伽玛刀研究基金会(International Gamma Knife Research Foundation)5家机构的数据,纳入初次SRS后≥12个月复发或持续库欣病且重复SRS后内分泌随访≥6个月的患者,共20例。
- 重复单次SRS在初次SRS后1.3-9.7年进行,中位内分泌随访6.6年(范围1.4-19.1年),中位边缘剂量20 Gy(范围10.8-35 Gy)。
主要发现
- 第二次SRS后12例(60%)获内分泌缓解,中位缓解时间6个月(范围2-64个月)。
- 初次缓解后2例(17%)出现生化复发。
- 5年和10年持久内分泌缓解累积率分别为47%和53%。
- 2例(10%)出现放射不良反应,包括短暂视力丧失和永久性复视。
临床怎么用
- 作者认为,对初次SRS后≥1年确认高皮质醇血症的经仔细选择的库欣病患者应考虑重复SRS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stereotactic radiosurgery (SRS) is frequently used for Cushing's disease (CD) after failed pituitary surgery. Management of patients with persistent CD after failed SRS is complex, as the alternative therapeutic options harbor significant risks. The outcomes of repeat pituitary radiosurgery, however, have not been described. We sought to determine the outcomes of repeat SRS in patients with CD. We pooled data from five institutions participating in the International Gamma Knife Research Foundation for patients with recurrent or persistent CD ≥ 12 months after initial SRS. Patients were included in the study if they had ≥ 6 months endocrine follow-up after repeat SRS. Twenty patients were included in the study. Repeat single-session SRS was performed 1.3-9.7 years after initial SRS. Median endocrine follow-up was 6.6 years (1.4-19.1 years). Median margin dose was 20 Gy (range 10.8-35 Gy). Endocrine remission after second SRS was noted in 12 patients (60%), with a median time to remission of 6 months (range 2-64 months). Biochemical recurrence occurred in two patients (17%) after initial remission. Overall, the cumulative rates of durable endocrine remission at 5 and 10 years were 47 and 53%, respectively. Two patients (10%) experienced adverse radiation effects, including transient visual loss and permanent diplopia. Repeat SRS achieves lasting biochemical remission in approximately half of patients with CD refractory to both prior microsurgery and SRS. Because of the morbidity of refractory or recurrent CD, repeat SRS should be considered for carefully selected patients with hypercortisolism confirmed one or more years after initial SRS.
引用
- Mehta GU, Ding D, Gupta A, et al. Repeat stereotactic radiosurgery for Cushing's disease: outcomes of an international, multicenter study. J Neurooncol. 2018. PMID: 29500664. doi:10.1007/s11060-018-2817-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。